Inactive

SOURCES SOUGHT NOTICE Solicitation Number: 75N95024Q00095_SS Title: Brand Name only: Revvity HTRF SARS-CoV2 capsid kit NAICS Code: 334516 - Analytical Laboratory Instrument Manufacturing NAICS Code Si... SOURCES SOUGHT NOTICE Solicitation Number: 75N95024Q00095_SS Title: Brand Name only: Revvity HTRF SARS-CoV2 capsid kit NAICS Code: 334516 - Analytical Laboratory Instrument Manufacturing NAICS Code Size Standard: 1,000 employees Description This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement, to determine the method of acquisition, and availability of domestic sources manufactured in the United States in sufficient and reasonably available commercial quantities and of a satisfactory quality. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Small businesses are encouraged to respond. Background Despite the emergence of effective vaccines and therapeutics, SARS-CoV-2 continues to present a major public health challenge globally. TDB Biology is committed to continuing development of novel molecules that can inhibit SARS-CoV-2 infection to meet this need. TDB Biology has developed an assay to measure the generation of the SARS-CoV-2 nucleocapsid in collaboration with Cisbio. In this assay an antibody combination is used to measure the levels of SARS-CoV-2 nucleocapsid, which is one of the main protein components of SARS-CoV-2. Cells are first infected with live SARS-CoV-2 or one of its variants and then as the virus replicates increasing levels of nucleocapsid can be detected by the binding of the two antibodies which produce a FRET signal. Cells treated with effective viral entry or replication inhibitors lead to a reduction in this FRET signal as less nucleocapsid is present in solution. Purpose and Objectives The purpose of this potential acquisition is to obtain a brand name only Revitty HTRF SARS-CoV2 capsid kit. Project Requirements Quantity:One (1) Item: Brand name name only of the Revitty HTRF SARS-CoV2 capsid kit The specific characteristics needed for this item are: 1) Use of Homogenous Time-Resolve Fluorescence compatible antibody pairs to measure concentration of SARS-CoV-2 nucleocapsid 2) Antibodies pair should be labeled with Eu Cryptate and d2 fluorphore 3) No wash, single step protocol for detection 4) Protocol validated to work for 96 and 384 well plates 5) Sensitive enough to measure SARS-CoV-2 nucleocapsid in both cultured media and lysate Contract Type and Anticipated Delivery Date The Government anticipates making one (1) award with a delivery date by the end of February, 2024. Required Information Responses must include information about the respondent’s current capability and capacity to deliver the brand name or equal equipment. If subcontracting is anticipated, responses should note the extent of subcontracting anticipated. Responses must also include – (1) UEI (Unique Entity Identifier) (2) organization name (3) organization address (4) point of contact (5) point of contact title, address, telephone, and email address (6) size and type of business (e.g., 8(a), HUBZone, etc.) pursuant the applicable NAICS code (7) place of manufacture (i.e. country) Interested companies are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. Submission Instructions and Due Date Responses must be submitted electronically to Samson Shifaraw, Contracting Officer, at samson.shifaraw@nih.gov. Responses must be received on or before 9:00am Eastern Time on Thursday, December 28, 2023. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Beta.SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).